EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”

Yoo-Na Kim, Je-Gun Joung, Eunhyang Park, Jae-Weon Kim, Jung Bok Lee, Jinyeong Lim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Jongsuk Chung, Byoung-Gie Kim, Jung-Yun Lee iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34786 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Yoo-Na Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit nennt 2 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsFemaleHumansAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialNeoplasm Recurrence, LocalPhthalazinesIndolesQuinazolinesAntibodies, MonoclonalPiperazines

Substanzen

PhthalazinescediranibIndolesQuinazolinesdurvalumabAntibodies, MonoclonalolaparibPiperazines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.
  • Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Clinical Epidemiology & Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, Korea.
  • Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology, Sungkyunkwan University, Seoul, Korea.

ORCID-Profile: Jung-Yun Lee

Zitieren

APA

Kim, Y. N., Joung, J. G., Park, E., Kim, J. W., Lee, J. B., Lim, J., Kim, S., Choi, C. H., Kim, H. S., Chung, J., Kim, B. G., & Lee, J. Y. (2024). Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”. International Journal of Cancer. https://doi.org/10.1002/ijc.34786

Vancouver

Kim YN, Joung JG, Park E, Kim JW, Lee JB, Lim J, et al. Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”. International Journal of Cancer. 2024. doi:10.1002/ijc.34786

BibTeX
@article{Kim2024,
  author = {Kim, Yoo-Na and Joung, Je-Gun and Park, Eunhyang and Kim, Jae-Weon and Lee, Jung Bok and Lim, Jinyeong and Kim, Sunghoon and Choi, Chel Hun and Kim, Hee Seung and Chung, Jongsuk and Kim, Byoung-Gie and Lee, Jung-Yun},
  title = {Reply to: Comments on “Randomized, two‐arm, non‐comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR ‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045”},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34786}
}
Kostenlos starten →